金币
UID7771
帖子
主题
积分2684
注册时间2011-11-28
最后登录1970-1-1
听众
性别保密
|

楼主 |
发表于 2013-10-25 12:25:49
|
显示全部楼层
lianlixiao 发表于 2013-10-24 15:05 
Testing samples from every container to determine identity may be valuable particularly for componen ...
The regulation at 21 CFR 211.84 requires that representative samples of each shipment of each lot shall be collected for testing. Some manufacturers have interpreted the CGMPs to require that each container in a shipment be sampled and tested for the attribute of identity. Testing samples from every container to determine identity may be valuable particularly for components purchased from distributors. (Analytical equipment and methods are readily available that permit rapid, non-destructive identification of material directly in containers in a warehouse area.) The CGMPs permit each drug product manufacturer to make its own decision as to the number of containers to sample, as long as the sampling plan is scientifically sound, leads to representative samples, and complies with the principles established at 21 CFR 211.84(b). An important caveat applies with respect to 21 CFR 211.84: samples are to be taken by the drug product manufacturer from containers after receipt (i.e., pre-shipment samples or so-called “piggyback” samples are generally not acceptable).
21 CFR 211.84条款要求每次到货每批次代表性样品应予以收集并检测。一些企业将其解读为CGMP要求每次到货对每个容器取样并测试均一性。向经销商购买的成分,用于测试均一性的可能特别贵重。(已有快速、非破坏性鉴别的分析仪器和方法可在仓库区直接用于容器。)CGMP要求每个企业自己决定容器取样数量,只要取样计划科学,取样有代表性,并符合21 CFR 211.84(b)的原则即可。21 CFR 211.84有关的重要警告:由药品生产商在收货后对容器取样(到货前取样或者所谓的“背负式”取样一般是不接受的)。
|
|